Troxerutin markets in China softened through January as a Lunar New Year lull coincided with rising inventories and subdued export demand. Early operations remained normal, but mid-January demand failed to recover as distributors drew on safety stocks rather than expanding purchases. A supply-heavy backdrop, driven by ample volumes and cautious buying, forced discounts to maintain shipment momentum before the holiday. End-use demand stayed subdued; domestic vascular-health generics and eye-health nutraceuticals bought minimal volumes, while cosmetics firms showed interest in Troxerutin actives for beauty formulations but did not convert short listings into orders. Export channels to India, Brazil, and the United States trimmed call-offs after stockpiling, leaving limited absorption for higher output. On the supply side, Rutin and solvents remained available with no bottlenecks, while capacity additions at Zhejiang Jianfeng and Chengzhi Life Science raised availability and widened inventories. The expected outlook is mixed, modest near-term upside through mid-2026, with a possible correction afterwards.
